Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: INTRAVACC B.V.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-09-01 to 2024-07-31
Current total value of award: $8063000
Description: TO DEVELOP AN INTRAMUSCULAR INACTIVATED WHOLE VIRUS VACCINE FROM EARLY PRODUCT SELECTION THROUGH A PHASE I CLINICAL TRIAL TO INDUCE PROTECTION AGAINST EV D68 INDUCED AFM.